XML 30 R29.htm IDEA: XBRL DOCUMENT v2.4.1.9
Segments (Tables)
 3 Months Ended
Mar. 31, 2015
Segment Reporting [Abstract]  
Information regarding our geographic activities
Information regarding our operations and assets for our operating segments and the unallocated corporate operations as well as geographic information are as follows:
 
For the three months ended March 31,
(In thousands)
2015
 
2014
Product revenues:
 
 
 
Pharmaceuticals
$
15,486

 
$
19,828

Diagnostics
—

 
—

Corporate
—

 
—

 
$
15,486

 
$
19,828

Revenue from services:
 
 
 
Pharmaceuticals
$
—

 
$
—

Diagnostics
2,009

 
1,910

Corporate
60

 
60

 
$
2,069

 
$
1,970

Revenue from transfer of intellectual property:
 
 
 
Pharmaceuticals
$
12,529

 
$
285

Diagnostics
—

 
191

Corporate
—

 
—

 
$
12,529

 
$
476

Operating (loss) income:
 
 
 
Pharmaceuticals
$
(37,924
)
 
$
(16,573
)
Diagnostics
(8,477
)
 
(7,078
)
Corporate
(9,979
)
 
(6,137
)
Less: Operating loss attributable to noncontrolling interests
(534
)
 
(489
)
 
$
(56,914
)
 
$
(30,277
)
Depreciation and amortization:
 
 
 
Pharmaceuticals
$
1,756

 
$
1,849

Diagnostics
1,747

 
1,691

Corporate
22

 
24

 
$
3,525

 
$
3,564

Net loss from investment in investees:
 
 
 
Pharmaceuticals
$
(1,761
)
 
$
(2,056
)
Diagnostics
—

 
—

Corporate
—

 
—

 
$
(1,761
)
 
$
(2,056
)
Revenues:
 
 
 
United States
$
2,493

 
$
2,446

Ireland
12,104

 
—

Chile
6,452

 
7,285

Spain
3,937

 
6,150

Israel
4,213

 
4,546

Mexico
885

 
1,831

Other
—

 
16

 
$
30,084

 
$
22,274


(In thousands)
March 31,
2015
 
December 31,
2014
Assets:
 
 
 
Pharmaceuticals
$
1,098,031

 
$
1,064,498

Diagnostics
105,751

 
108,072

Corporate
308,467

 
95,094

 
$
1,512,249

 
$
1,267,664

Goodwill:

 

Pharmaceuticals
$
172,254

 
$
173,327

Diagnostics
50,965

 
50,965

Corporate
—

 
—

 
$
223,219

 
$
224,292